AGIO Agios Pharmaceuticals Inc

Price (delayed)

$55.23

Market cap

$3.86B

P/E Ratio

2.42

Dividend/share

N/A

EPS

$22.8

Enterprise value

$2.08B

Sector: Healthcare
Industry: Biotechnology

Highlights

The debt has declined by 7% year-on-year
Agios Pharmaceuticals's gross profit has decreased by 43% QoQ but it has increased by 31% YoY
The revenue has declined by 43% since the previous quarter but it has grown by 32% year-on-year

Key stats

What are the main financial stats of AGIO
Market
Shares outstanding
69.94M
Market cap
$3.86B
Enterprise value
$2.08B
Valuations
Price to earnings (P/E)
2.42
Price to book (P/B)
1.67
Price to sales (P/S)
33.08
EV/EBIT
1.31
EV/EBITDA
1.29
EV/Sales
17.9
Earnings
Revenue
$116.1M
EBIT
$1.59B
EBITDA
$1.61B
Free cash flow
-$317.62M
Per share
EPS
$22.8
Free cash flow per share
-$4.57
Book value per share
$33
Revenue per share
$1.67
TBVPS
$35.78
Balance sheet
Total assets
$2.49B
Total liabilities
$191.8M
Debt
$103.61M
Equity
$2.3B
Working capital
$2.26B
Liquidity
Debt to equity
0.05
Current ratio
24.4
Quick ratio
24.2
Net debt/EBITDA
-1.11
Margins
EBITDA margin
1,383.7%
Gross margin
98%
Net margin
1,367.1%
Operating margin
-313.7%
Efficiency
Return on assets
121.5%
Return on equity
170%
Return on invested capital
185.7%
Return on capital employed
66.4%
Return on sales
1,367.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AGIO stock price

How has the Agios Pharmaceuticals stock price performed over time
Intraday
0.51%
1 week
-1%
1 month
3.5%
1 year
23.42%
YTD
27.46%
QTD
6.95%

Financial performance

How have Agios Pharmaceuticals's revenue and profit performed over time
Revenue
$116.1M
Gross profit
$113.83M
Operating income
-$364.17M
Net income
$1.59B
Gross margin
98%
Net margin
1,367.1%
The operating margin has dropped by 102% since the previous quarter but it has increased by 34% year-on-year
Agios Pharmaceuticals's gross profit has decreased by 43% QoQ but it has increased by 31% YoY
The revenue has declined by 43% since the previous quarter but it has grown by 32% year-on-year
Agios Pharmaceuticals's operating income has decreased by 15% from the previous quarter but it has increased by 12% YoY

Growth

What is Agios Pharmaceuticals's growth rate over time

Valuation

What is Agios Pharmaceuticals stock price valuation
P/E
2.42
P/B
1.67
P/S
33.08
EV/EBIT
1.31
EV/EBITDA
1.29
EV/Sales
17.9
The P/B is 70% below the 5-year quarterly average of 5.5 and 68% below the last 4 quarters average of 5.2
The revenue has declined by 43% since the previous quarter but it has grown by 32% year-on-year
AGIO's P/S is 25% above its last 4 quarters average of 26.4 but 19% below its 5-year quarterly average of 40.7

Efficiency

How efficient is Agios Pharmaceuticals business performance

Dividends

What is AGIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AGIO.

Financial health

How did Agios Pharmaceuticals financials performed over time
The total assets has surged by 192% since the previous quarter
AGIO's current ratio has surged by 190% year-on-year
The debt is 95% smaller than the equity
The debt to equity has shrunk by 81% QoQ and by 72% YoY
The debt has declined by 7% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.